The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
=== Allegations of steroid use and National Baseball Hall of Fame === Bagwell was eligible for induction into the Baseball Hall of Fame for the first time in 2011. Speculation abounded that some baseball writers initially refrained from voting for Bagwell on the premise that he used performance-enhancing drugs, since most of his playing career took place during what is commonly referred to as "the steroid era." In spite of the speculation, as of 2016, no concrete evidence has surfaced linking him to the use of performance-enhancing drugs. However, one report indicates that he disclosed use of androstenedione to a Houston Chronicle reporter in 1998. At that time, neither the FDA nor MLB had banned its use. Bagwell has not been connected with any of the 104 positive samples in the 2003 survey tests that were leaked. Bagwell was not among the 89 players named in the Mitchell Report released in 2007. Longtime Atlanta Braves manager Bobby Cox said the following about Bagwell: "Jeff Bagwell was [in Houston] for so long and starred every year. For me a guy that dominated like that for one team, even in the league stats through the years. His are up there with anybody's. I would put him in right away. So he would get my vote on the first ballot." Still, in spite of the speculation that Bagwell used performance-enhancing drugs, San Francisco Chronicle sportswriter Bruce Jenkins wrote that Bagwell did not have the credentials to be in the Hall of Fame. In July 2015, he acknowledged "that many are suspicious of Bagwell—without proof, as you say.
== Chemistry == Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4-propionylpiperidine. It is usually available as the hydrochloride, which is a white powder. It is synthesized by alkylating (3-methoxyphenyl)acetonitrile with bis(2-chloroethyl)methylamine, followed by reaction with ethylmagnesium bromide, and finally O-demethylation with hydrobromic acid. Because of a strong vesicant nature of bis(2-chloroethyl)methylamine there are many other routes developed for obtaining ketobemidone. A route depicted below lays through first alkylating the same (3-methoxyphenyl)acetonitrile with 2-chloro-N,N-dimethylethylamine or 2-chloro-N-benzyl-N-methylethylamine. Next, those amines are alkylated once again using a mixed 1-bromo-2-chloroethane, thus completing the piperidine ring and obtaining a quaternary ammonium salt, which can be dequaternized using thiophenol salt (for N,N-dimethylammonium) or catalytic hydrogenation (for both compounds) to a common 4-(3-methoxyphenyl)-4-cyano-1-methyl-pyperidine. The latter yields ketobemidone after Grignard reaction with ethylmagnesium bromide and ether cleavage.
Protactinium(V) chloride has a polymeric structure of monoclinic symmetry. There, within one polymeric chain, all chlorine atoms lie in one graphite-like plane and form planar pentagons around the protactinium ions. The 7-coordination of protactinium originates from the five chlorine atoms and two bonds to protactinium atoms belonging to the nearby chains. It easily hydrolyzes in water. It melts at 300 °C and sublimates at even lower temperatures. Protactinium(V) fluoride can be prepared by reacting protactinium oxide with either bromine pentafluoride or bromine trifluoride at about 600 °C, and protactinium(IV) fluoride is obtained from the oxide and a mixture of hydrogen and hydrogen fluoride at 600 °C; a large excess of hydrogen is required to remove atmospheric oxygen leaks into the reaction. Protactinium(V) chloride is prepared by reacting protactinium oxide with carbon tetrachloride at temperatures of 200–300 °C. The by-products (such as PaOCl3) are removed by fractional sublimation. Reduction of protactinium(V) chloride with hydrogen at about 800 °C yields protactinium(IV) chloride – a yellow-green solid that sublimes in vacuum at 400 °C. It can also be obtained directly from protactinium dioxide by treating it with carbon tetrachloride at 400 °C. Protactinium bromides are produced by the action of aluminium bromide, hydrogen bromide, carbon tetrabromide, or a mixture of hydrogen bromide and thionyl bromide on protactinium oxide. They can alternatively be produced by reacting protactinium pentachloride with hydrogen bromide or thionyl bromide.
Progonadoliberin-2 is a protein that in humans is encoded by the GNRH2 gene. The protein encoded by this gene is a preproprotein that is cleaved to form a secreted 10 aa peptide hormone, QHWSHGWYPG. The secreted decapeptide regulates reproduction in females by stimulating the secretion of both luteinizing- and follicle-stimulating hormones. Three transcript variants that encode unique proproteins but the same peptide hormone have been found for this gene. The peptide belongs to gonadotropin-releasing hormone family. Most vertebrate species possess two or three forms of gonadotropin-releasing hormone (GnRH) expressed in three distinct brain regions. Although the function of the hypothalamic form (GnRH1; common to many vertebrates), in controlling the reproductive axis has been defined, the functions of the other two isoforms (GnRH2 and GnRH3) remain largely unknown. The presence and conservation of GnRH2 across vertebrate species indicate important biological roles, but the absence of GnRH2 in rodents has greatly hampered the use of these vertebrate models and modern molecular tools to pursue its functions. A relatively well-documented function of GnRH2 is that the administration of GnRH2 has anorexigenic effects in female musk shrew, mouse, goldfish and zebrafish, but the mechanisms are still unclear.
=== Garret: The King of Tustin === First aired: Online Robert and Kyle have one major problem: Garrett. This self-proclaimed King of Tustin makes their lives miserable. The Queen of Tustin is crowned, courtesy of MMA Middleweight Jake Shields.
Sources: en.wikipedia.org
The three substrates of this enzyme are D-erythrose 4-phosphate, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are 4-phospho-D-erythronic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-erythrose 4-phosphate:NAD+ oxidoreductase. Other names in common use include erythrose 4-phosphate dehydrogenase, E4PDH, GapB, Epd dehydrogenase, and E4P dehydrogenase. This enzyme participates in vitamin B6 metabolism (see DXP-dependent biosynthesis of pyridoxal phosphate).
==== Lieutenant of the Royal Victorian Order (LVO) ==== Hamish Blair, Senior Executive Officer, Scottish Office. Captain Robert Neil Blair, Royal Navy, Private Secretary to The Duke of York and to Princess Alexandra, the Honourable Lady Ogilvy. Laurence Albert Brown. For services to the Royal Collection. Donald Reeve Buttress, Surveyor of the Fabric, Westminster Abbey. Bernard Joseph Frahm, . For services to the Crown on Royal Visits to New Zealand. Commander Thomas Dixon Laidlaw, , Metropolitan Police. Leonora Mary, The Countess of Lichfield, Extra Lady in Waiting to The Princess Royal. Allan Arthur Percival, lately Press Secretary to The Prince of Wales. Alexander Hay Sutherland, Chief Publicity Officer, Scottish Office.
More observational evidence was published throughout the 1930s, and in 1938, Science published a paper showing that tobacco smokers live substantially shorter lives. It built a survival curve from family history records kept at the Johns Hopkins School of Hygiene and Public Health. This result was ignored or incorrectly explained away. An association between smoking tobacco and heart attacks was first mentioned in 1930; a large case–control study found a significant association in 1940, but avoided saying anything about cause, on the grounds that such a conclusion would cause controversy and doctors were not yet ready for it. Official hostility to tobacco use was widespread in Nazi Germany, where case-control studies were published in 1939 and 1943. The Institute for the Struggle against the Dangers of Tobacco (German: Wissenschaftliches Institut zur Erforschung der Tabakgefahren) was set up at the University of Jena in 1942. It was one of the first scientific institutes to discover the dangers of smoking tobacco, including the link between smoking and lung cancer. However, due to its relationship with the Nazi regime, its work was not taken seriously after the Second World War. Another was published in the Netherlands in 1948. A case-control study on lung cancer and smoking, done in 1939 by Franz Hermann Müller, had serious weaknesses in its methodology, but study design problems were better addressed in subsequent studies.
https://www.bioinformatics.nl/tools/pam.html Website that calculates a PAM matrix for any level. https://ftp.ncbi.nih.gov/repository/blocks/unix/blosum/MDM/ for PAM matrices from 1992 (PAM80, 120, 160, 210, 250 calculated using the "pam" program and PAM250 from Gonnet, Cohen & Benner 1992) https://www.ncbi.nlm.nih.gov/IEB/ToolBox/C_DOC/lxr/source/data/ for PAM30, PAM70, and PAM250 in the NCBI C Toolkit. https://github.com/ncbi/ncbi-cxx-toolkit-public/tree/main/src/util/tables for the same tables in the NCBI C++ Toolkit. https://ftp.ncbi.nih.gov/blast/matrices/ NCBI "Bonus Matrices" for BLAST, includes PAM10–500 and many other matrices. Also includes the source code for the "pam" program, which multiplies the data from Dayhoff to extrapolate other PAM values. Later derivations of PAM-type matrices:
where K is an optical constant and c is the solution concentration. Using a differential refractometer (DRI) to measure the concentration of the solution, an absolute molar mass can be calculated. More accurate measurements can be made by using a low-angle static light scattering (LALS) detector, which operates at a very low angle and therefore do not require angular effects to be corrected. However, these detectors are very sensitive to particles, which leads to noisy data and are therefore rarely used. LALS detectors have largely been replaced by MALS detectors, which measures scattered light at multiple angles simultaneously and extrapolates the data to θ = 0° to obtain a weight-average molar mass. The coupling of SEC with MALS detection have become the benchmark for the determination of absolute molecular mass, particularly averages masses and distributions. Viscometry detectors, although less common, also function as detectors of absolute molar mass. Unlike light scattering photometers which do not use a calibration curve, viscometers apply a universal calibration curve where the logarithm of intrinsic viscosity multiplied by molar mass can be plotted against the retention volume from SEC. This method is effective for calculating the absolute molar mass of a wide variety of polymers, including rod-like polymers and dendrimers. Several other methods of analysis are used to determine the absolute molar mass.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.